Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.

de Langen AJ, Jebbink M, Hashemi SMS, Kuiper JL, de Bruin-Visser J, Monkhorst K, Thunnissen E, Smit EF.

Br J Cancer. 2018 Jul 31. doi: 10.1038/s41416-018-0194-7. [Epub ahead of print]

PMID:
30061586
2.

Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.

Jansen RW, van Amstel P, Martens RM, Kooi IE, Wesseling P, de Langen AJ, Menke-Van der Houven van Oordt CW, Jansen BHE, Moll AC, Dorsman JC, Castelijns JA, de Graaf P, de Jong MC.

Oncotarget. 2018 Apr 13;9(28):20134-20155. doi: 10.18632/oncotarget.24893. eCollection 2018 Apr 13. Review.

3.

Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.

van Veggel B, de Langen AJ, Hashemi SMS, Monkhorst K, Heideman DAM, Thunnissen E, Smit EF.

J Thorac Oncol. 2018 Aug;13(8):1222-1226. doi: 10.1016/j.jtho.2018.04.012. Epub 2018 Apr 24.

PMID:
29702285
4.

Repeatability of quantitative 18F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis.

Kramer GM, Liu Y, de Langen AJ, Jansma EP, Trigonis I, Asselin MC, Jackson A, Kenny L, Aboagye EO, Hoekstra OS, Boellaard R; QuIC-ConCePT consortium.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):951-961. doi: 10.1007/s00259-017-3923-x. Epub 2018 Jan 23.

5.

Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.

Plenker D, Bertrand M, de Langen AJ, Riedel R, Lorenz C, Scheel AH, Müller J, Brägelmann J, Daßler-Plenker J, Kobe C, Persigehl T, Kluge A, Wurdinger T, Schellen P, Hartmann G, Zacherle T, Menon R, Thunnissen E, Büttner R, Griesinger F, Wolf J, Heukamp L, Sos ML, Heuckmann JM.

Clin Cancer Res. 2018 Mar 15;24(6):1337-1343. doi: 10.1158/1078-0432.CCR-17-3001. Epub 2017 Dec 28.

PMID:
29284707
6.

PD-L1 IHC in NSCLC with a global and methodological perspective.

Thunnissen E, de Langen AJ, Smit EF.

Lung Cancer. 2017 Nov;113:102-105. doi: 10.1016/j.lungcan.2017.09.010. Epub 2017 Sep 18. Review.

7.

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib.

Muller IB, de Langen AJ, Giovannetti E, Peters GJ.

Onco Targets Ther. 2017 Sep 13;10:4535-4541. doi: 10.2147/OTT.S109493. eCollection 2017. Review.

8.

Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets.

Best MG, Sol N, In 't Veld SGJG, Vancura A, Muller M, Niemeijer AN, Fejes AV, Tjon Kon Fat LA, Huis In 't Veld AE, Leurs C, Le Large TY, Meijer LL, Kooi IE, Rustenburg F, Schellen P, Verschueren H, Post E, Wedekind LE, Bracht J, Esenkbrink M, Wils L, Favaro F, Schoonhoven JD, Tannous J, Meijers-Heijboer H, Kazemier G, Giovannetti E, Reijneveld JC, Idema S, Killestein J, Heger M, de Jager SC, Urbanus RT, Hoefer IE, Pasterkamp G, Mannhalter C, Gomez-Arroyo J, Bogaard HJ, Noske DP, Vandertop WP, van den Broek D, Ylstra B, Nilsson RJA, Wesseling P, Karachaliou N, Rosell R, Lee-Lewandrowski E, Lewandrowski KB, Tannous BA, de Langen AJ, Smit EF, van den Heuvel MM, Wurdinger T.

Cancer Cell. 2017 Aug 14;32(2):238-252.e9. doi: 10.1016/j.ccell.2017.07.004.

9.

Resistance Mechanisms to AZD9291 and Rociletinib-Letter.

Van Der Steen N, Rolfo C, Pauwels P, de Langen AJ, Peters GJ, Giovannetti E.

Clin Cancer Res. 2017 Jul 15;23(14):3966. doi: 10.1158/1078-0432.CCR-17-0167. No abstract available.

10.

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.

Bubendorf L, Lantuejoul S, de Langen AJ, Thunnissen E.

Eur Respir Rev. 2017 Jun 28;26(144). pii: 170007. doi: 10.1183/16000617.0007-2017. Print 2017 Jun 30. Review.

11.

High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes.

van de Ven R, Niemeijer AN, Stam AGM, Hashemi SMS, Slockers CG, Daniels JM, Thunnissen E, Smit EF, de Gruijl TD, de Langen AJ.

ERJ Open Res. 2017 May 23;3(2). pii: 00110-2016. doi: 10.1183/23120541.00110-2016. eCollection 2017 Apr.

12.

Baseline and longitudinal variability of normal tissue uptake values of [18F]-fluorothymidine-PET images.

Cysouw MCF, Kramer GM, Frings V, De Langen AJ, Wondergem MJ, Kenny LM, Aboagye EO, Kobe C, Wolf J, Hoekstra OS, Boellaard R.

Nucl Med Biol. 2017 Aug;51:18-24. doi: 10.1016/j.nucmedbio.2017.05.002. Epub 2017 May 10.

13.

Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.

de Langen AJ, Smit EF.

Ther Adv Med Oncol. 2017 Jan;9(1):46-58. doi: 10.1177/1758834016670555. Epub 2016 Oct 3. Review.

14.

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer.

van der Wekken AJ, Pelgrim R, 't Hart N, Werner N, Mastik MF, Hendriks L, van der Heijden EHFM, Looijen-Salamon M, de Langen AJ, Staal-van den Brekel J, Riemersma S, van den Borne BE, Speel EJM, Dingemans AC, Hiltermann TJN, van den Berg A, Timens W, Schuuring E, Groen HJM.

Clin Cancer Res. 2017 Aug 1;23(15):4251-4258. doi: 10.1158/1078-0432.CCR-16-1631. Epub 2017 Feb 9.

15.

Accuracy and Precision of Partial-Volume Correction in Oncological PET/CT Studies.

Cysouw MCF, Kramer GM, Hoekstra OS, Frings V, de Langen AJ, Smit EF, van den Eertwegh AJ, Oprea-Lager DE, Boellaard R.

J Nucl Med. 2016 Oct;57(10):1642-1649. Epub 2016 May 26.

16.

Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.

Kramer GM, Frings V, Hoetjes N, Hoekstra OS, Smit EF, de Langen AJ, Boellaard R.

J Nucl Med. 2016 Sep;57(9):1343-9. doi: 10.2967/jnumed.115.170225. Epub 2016 Apr 21.

17.

Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer.

Tekatli H, Haasbeek N, Dahele M, De Haan P, Verbakel W, Bongers E, Hashemi S, Nossent E, Spoelstra F, de Langen AJ, Slotman B, Senan S.

J Thorac Oncol. 2016 Jul;11(7):1081-9. doi: 10.1016/j.jtho.2016.03.008. Epub 2016 Mar 21.

18.

Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.

Dickhoff C, Dahele M, Paul MA, van de Ven PM, de Langen AJ, Senan S, Smit EF, Hartemink KJ.

Lung Cancer. 2016 Apr;94:108-13. doi: 10.1016/j.lungcan.2016.02.005. Epub 2016 Feb 11.

PMID:
26973215
19.

Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation.

van Velden FH, Kramer GM, Frings V, Nissen IA, Mulder ER, de Langen AJ, Hoekstra OS, Smit EF, Boellaard R.

Mol Imaging Biol. 2016 Oct;18(5):788-95. doi: 10.1007/s11307-016-0940-2.

20.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013.

Dickhoff C, Dahele M, de Langen AJ, Paul MA, Smit EF, Senan S, Hartemink KJ, Damhuis RA.

J Thorac Oncol. 2016 Apr;11(4):566-72. doi: 10.1016/j.jtho.2016.01.002. Epub 2016 Jan 8.

21.

Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with ¹⁸F-Fluoroazomycin Arabinoside and ¹⁵O-H₂O PET.

Iqbal R, Kramer GM, Verwer EE, Huisman MC, de Langen AJ, Bahce I, van Velden FH, Windhorst AD, Lammertsma AA, Hoekstra OS, Boellaard R.

J Nucl Med. 2016 Apr;57(4):530-5. doi: 10.2967/jnumed.115.166579. Epub 2015 Dec 10.

22.

Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.

Muller IB, De Langen AJ, Honeywell RJ, Giovannetti E, Peters GJ.

Expert Rev Anticancer Ther. 2016;16(2):147-57. doi: 10.1586/14737140.2016.1131612. Epub 2016 Jan 4. Review.

PMID:
26654422
23.

Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.

Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, Heideman DA, Berk Y, Buijs EJ, Speel EJ, Krouwels FH, Smit HJ, Groen HJ, Dingemans AM, Smit EF.

Lung Cancer. 2015 Sep;89(3):255-61. doi: 10.1016/j.lungcan.2015.05.023. Epub 2015 Jun 6.

PMID:
26117231
24.

Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer.

Frings V, de Langen AJ, Yaqub M, Schuit RC, van der Veldt AA, Hoekstra OS, Smit EF, Boellaard R.

Mol Imaging Biol. 2014 Feb;16(1):136-45. doi: 10.1007/s11307-013-0658-3.

PMID:
23813332
25.

Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis.

de Langen AJ, Vincent A, Velasquez LM, van Tinteren H, Boellaard R, Shankar LK, Boers M, Smit EF, Stroobants S, Weber WA, Hoekstra OS.

J Nucl Med. 2012 May;53(5):701-8. doi: 10.2967/jnumed.111.095299. Epub 2012 Apr 10.

26.

Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment.

Cheebsumon P, van Velden FH, Yaqub M, Frings V, de Langen AJ, Hoekstra OS, Lammertsma AA, Boellaard R.

J Nucl Med. 2011 Oct;52(10):1550-8. doi: 10.2967/jnumed.111.088914. Epub 2011 Aug 17.

27.

Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI.

de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, Pruim J, Brans B, Leffers P, Dingemans AM, Smit EF, Groen HJ, Hoekstra OS.

J Nucl Med. 2011 Jan;52(1):48-55. doi: 10.2967/jnumed.110.078261. Epub 2010 Dec 13.

28.

Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.

Frings V, de Langen AJ, Smit EF, van Velden FH, Hoekstra OS, van Tinteren H, Boellaard R.

J Nucl Med. 2010 Dec;51(12):1870-7. doi: 10.2967/jnumed.110.077255. Epub 2010 Nov 15.

29.

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.

Dingemans AM, de Langen AJ, van den Boogaart V, Marcus JT, Backes WH, Scholtens HT, van Tinteren H, Hoekstra OS, Pruim J, Brans B, Thunnissen FB, Smit EF, Groen HJ.

Ann Oncol. 2011 Mar;22(3):559-66. doi: 10.1093/annonc/mdq391. Epub 2010 Aug 11.

PMID:
20702788
30.

Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.

de Langen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, Slotman BJ, de Bree R, Smit EF, Hoekstra OS, Lammertsma AA.

Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):389-95. doi: 10.1007/s00259-008-0960-5. Epub 2008 Oct 18.

PMID:
18931838
31.

Reproducibility of tumor perfusion measurements using 15O-labeled water and PET.

de Langen AJ, Lubberink M, Boellaard R, Spreeuwenberg MD, Smit EF, Hoekstra OS, Lammertsma AA.

J Nucl Med. 2008 Nov;49(11):1763-8. doi: 10.2967/jnumed.108.053454. Epub 2008 Oct 16.

32.

Use of H2(15)O-PET and DCE-MRI to measure tumor blood flow.

de Langen AJ, van den Boogaart VE, Marcus JT, Lubberink M.

Oncologist. 2008 Jun;13(6):631-44. doi: 10.1634/theoncologist.2007-0235. Review.

33.

Automated detection of malaria pigment: feasibility for malaria diagnosing in an area with seasonal malaria in northern Namibia.

de Langen AJ, van Dillen J, de Witte P, Mucheto S, Nagelkerke N, Kager P.

Trop Med Int Health. 2006 Jun;11(6):809-16.

34.

The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis.

de Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS.

Eur J Cardiothorac Surg. 2006 Jan;29(1):26-9. Epub 2005 Dec 6. Review.

PMID:
16337397

Supplemental Content

Loading ...
Support Center